A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this study, we analyzed the outcome of 809 patients with R/R DLBCL after two or more previous lines of treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachy, Emmanuel, Le Gouill, Steven, Di Blasi, Roberta, Sesques, Pierre, Manson, Guillaume, Cartron, Guillaume, Beauvais, David, Roulin, Louise, Gros, François Xavier, Rubio, Marie Thérèse, Bories, Pierre, Bay, Jacques Olivier, Llorente, Cristina Castilla, Choquet, Sylvain, Casasnovas, René-Olivier, Mohty, Mohamad, Guidez, Stéphanie, Joris, Magalie, Loschi, Michaël, Carras, Sylvain, Abraham, Julie, Chauchet, Adrien, Drieu La Rochelle, Laurianne, Deau-Fischer, Bénédicte, Hermine, Olivier, Gastinne, Thomas, Tudesq, Jean Jacques, Gat, Elodie, Broussais, Florence, Thieblemont, Catherine, Houot, Roch, Morschhauser, Franck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556323/
https://www.ncbi.nlm.nih.gov/pubmed/36138152
http://dx.doi.org/10.1038/s41591-022-01969-y

Ejemplares similares

Ejemplares similares